Study summary
A blood test after surgery sorted high-risk from low-risk stage III colon cancer
87%free of recurrence at 3 years if ctDNA-negative, vs 49% if positive
What was tested
Circulating tumor DNA (ctDNA) blood testing after surgery to lighten chemotherapy for ctDNA-negative people and intensify it for ctDNA-positive people, against standard care.
What they found
- 3-year recurrence-free survival was 87% if ctDNA-negative vs 49% if positive.
- Lighter treatment cut oxaliplatin use (34.8% vs 88.6%) but recurrence-free survival was slightly lower (85.3% vs 88.1%).
- Stronger chemotherapy did not help ctDNA-positive people.
What it means
ctDNA predicts risk well; how to act on it is still being tested.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.